Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Altman

Showing results (351-360 of 365) with videos related to

Pageof 37
Sort By:
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Blood Advances|April 15, 2026
PTP4A2 Promotes Leukemogenesis through Inhibiting the p53 Tumor Suppressor Signaling Pathway in Leukemia-initiating CellsShiyu Xiao, Michihiro Kopbayashi, Yunpeng Bai, et al.
Blood|June 1, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapyVanessa E Kennedy, Cheryl A C Peretz, Anushka Walia, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyMartin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2025
Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AMLEunice S Wang, Pau Montesinos, James Foran, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Pageof 37

Showing results (351-360 of 365) with videos related to

Sort By:
Pageof 37
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Blood Advances|April 15, 2026
PTP4A2 Promotes Leukemogenesis through Inhibiting the p53 Tumor Suppressor Signaling Pathway in Leukemia-initiating CellsShiyu Xiao, Michihiro Kopbayashi, Yunpeng Bai, et al.
Blood|June 1, 2026
Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapyVanessa E Kennedy, Cheryl A C Peretz, Anushka Walia, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Daniel A Pollyea, Dale Bixby, Alexander Perl, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in OncologyMartin S Tallman, Eunice S Wang, Jessica K Altman, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 8, 2023
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in OncologyDaniel A Pollyea, Jessica K Altman, Rita Assi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2025
Ziftomenib in Relapsed or Refractory <i>NPM1</i>-Mutated AMLEunice S Wang, Pau Montesinos, James Foran, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 9, 2017
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in OncologyMargaret R O'Donnell, Martin S Tallman, Camille N Abboud, et al.
Pageof 37